ReviewInternational journal of nanomedicine2025
Cross - Kingdom Dialogue of Microbial Messengers: Multi - Target Regulatory Mechanisms and Therapeutic Strategies of Gut Microbiota - Derived Extracellular Vesicles in Metabolic Diseases.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Probiotics and Extracellular Vesicles as Redox Modulators in Wound Healing: From Microbial Therapeutics to Engineered Nanotherapeutic Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Holobiontic Intercellular Relationships Between the Oral Cavity and the Rest of the Human Organism: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Neurovascular Impairment in Type 2 Diabetes Mellitus: The Role of Adipocyte-Derived Exosomes.Biomolecules · 2026Review
- Extracellular Vesicles in Gestational Diabetes Mellitus: Pathogenesis, Diagnosis, and Therapy.International journal of nanomedicine · 2026Review
- Protective Effects of Orally AdministeredInternational journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota-derived extracellular vesicles (GMEVs) serve as pivotal mediators of cross-communication between microorganisms and their hosts, playing a complex and central role in the onset and progression of metabolic diseases. This review systematically summarizes the biological characteristics, molecular composition, and regulatory mechanisms of GMEVs in metabolic disorders such as obesity, diabetes, and non-alcoholic fatty liver disease. GMEVs facilitate dialogue along the "gut-organ axis" by transporting active molecules such as lipopolysaccharides (LPS), flagellin, nucleic acids, and metabolic products, thereby mediating bidirectional regulation of host metabolic homeostasis. GMEVs derived from pathogenic bacteria promote metabolic inflammation and insulin resistance by compromising the intestinal barrier, activating inflammatory pathways, and inhibiting insulin signaling. Conversely, GMEVs originating from probiotics exert protective effects by enhancing tight junction functionality, modulating immune responses, and improving lipid metabolism. Notably, the dynamic fluctuations of GMEVs are closely linked to disease progression, and their microbiota-specific molecular characteristics offer novel biomarkers for the early diagnosis of metabolic diseases. Despite the challenges posed by standardization of isolation and elucidation of underlying mechanisms, the potential applications of GMEVs in the precise prevention and treatment of metabolic diseases are vast, providing a theoretical foundation for the development of novel microbiome-based intervention strategies. Future research should further elucidate the heterogeneity of GMEVs and their spatiotemporal dynamics in host interactions, facilitating the transition from fundamental research to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.